Coherus BioSciences Balance Sheet Health
Financial Health criteria checks 2/6
Coherus BioSciences has a total shareholder equity of $-88.0M and total debt of $264.5M, which brings its debt-to-equity ratio to -300.7%. Its total assets and total liabilities are $505.0M and $593.0M respectively.
Key information
-300.7%
Debt to equity ratio
US$264.51m
Debt
| Interest coverage ratio | n/a |
| Cash | US$97.69m |
| Equity | -US$87.97m |
| Total liabilities | US$592.97m |
| Total assets | US$505.00m |
Recent financial health updates
No updates
Recent updates
There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise
Dec 21
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
Dec 16Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%
Nov 06Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive
Sep 22Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Aug 13Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S
Aug 07Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
May 31Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now
May 23Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Mar 21Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive
Feb 03Coherus BioSciences: FDA Approvals Spice Up The Pipeline
Jan 17Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues
Dec 20The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically
May 13Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3
Sep 19Coherus: 2022 Is In Many Ways A Make Or Break Year
Aug 24Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli
Aug 03Financial Position Analysis
Short Term Liabilities: CHRS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: CHRS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: CHRS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: CHRS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CHRS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CHRS has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 17.4% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 08:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Coherus BioSciences, Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |